Cryocompression May Mitigate Chemo-Induced Neuropathy in Gynecologic Cancers

Video

Investigators report that most patients with gynecologic cancers were able to tolerate cryocompression to help manage chemotherapy-induced neuropathy, according to an expert from Duke University Medical Center.

Cryocompression may help to prevent peripheral neuropathy related to chemotherapy for patients diagnosed with gynecologic cancers without additional burden, according to Mary Katherine Montes de Oca, MD.

During The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, about data from a study evaluating the efficacy and patient-reported outcomes of cryocompression in preventing peripheral neuropathy following chemotherapy for gynecologic cancers as well as patient-reported.

In the self-controlled trial, over 70% of patients reported cryocompression was very tolerable with each cycle, and over 80% “agreed” or “strongly agreed” that cryocompression was acceptable and planned to continue with the intervention during future chemotherapy. Additionally, patients undergoing cryocompression were 39% less likely to report Patient Neurotoxicity Questionnaire grade of C or less symptoms of peripheral neuropathy compared with a control group of patients who did not undergo cryocompression.

Transcript:

We found that cryocompression therapy significantly prevented subjective symptoms of neuropathy. We didn’t find any differences in objective neuropathy between groups, and we found that patients overall were able to tolerate the cryocompression really well.

There’s a theoretical concern of frostbite from the ice on the hands and feet. We didn’t have any adverse [effects] from use of the cryocompression. There were 2 patients who weren’t able to tolerate the treatment. But the compression therapy can also allow for a barrier between the patient’s fingertips and the ice.

I hope that [my colleagues] take away that cryocompression can prevent chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Hopefully, it is something that is easy, accessible, and [is something] that can be recommend to patients without creating additional burden on them during chemotherapy.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Related Content